tyrosine kinase inhibitor

Also found in: Dictionary, Medical, Acronyms, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to tyrosine kinase inhibitor

a drug used in cases of chronic myeloid leukemia

References in periodicals archive ?
Unique cutaneous reaction to secondand third-generation tyrosine kinase inhibitors for chronic myeloid leukemia.
It is considered the current standard of care to use epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) as a first line treatment in patients with activating EGFR mutations.
He was started on tyrosine kinase inhibitor sunitinib 50mg OD for 4 weeks/2 week off schedule in May 2012.
2006) EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Currently, no targeted tyrosine kinase inhibitor therapies are specifically approved for KRAS mutations.
These data suggest a way in which receptor tyrosine kinase inhibitors could be used to treat individuals with KRAS mutant colorectal cancers.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
The side effect profile and therapeutic window of the antibody agents and tyrosine kinase inhibitors (TKIs) differ, as does their clinical activity, across different gastrointestinal tumour types.
It was discovered by Kyowa Hakko Kirin and is an oral, once-daily and vascular endothelial growth factor tyrosine kinase inhibitor.
The combination will be assessed as a second line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the T790M resistance mutation.
Through the acquisition, Celgene gains a highly-selective Brutona[euro](tm)s tyrosine kinase inhibitor which is presently in Phase I development as well as Avilaa[euro](tm)s Avilomics protein silencing platform.
Based upon the FDA approval status of dasatinib for lymphoblastic leukemia, this drug or a related tyrosine kinase inhibitor may prove useful in attenuating oligomer-dependent microgliosis and proinflammatory changes in the brain.
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Full browser ?